Qilu Hospital of Shandong University, Jinan, China.
Shandong Provincial Hospital affiliated to Shandong First Medical College, Jinan, China.
Int J Hyperthermia. 2021;38(1):691-695. doi: 10.1080/02656736.2021.1915503.
To retrospectively evaluate early clinical outcomes of percutaneous microwave ablation (MWA) for stage T1a renal cell carcinomas (RCCs) in solitary kidney patients.
15 solitary kidney patients with 16 stage T1a N0M0 biopsy-proved RCCs underwent CT-guided percutaneous microwave ablation between October 2016 and July 2020. The patients were followed up with contrast-enhanced computed tomography or magnetic resonance imaging at 1, 3, and 6 months and every 6 months thereafter. Serum creatinine levels of each patient pre MWA, 1 day after MWA and the most recent record were collected. Technical effectiveness, local recurrence, survival rates and complications were accessed.
Complete ablation was achieved in all 16 tumors (100%) including 13 clear cell carcinomas and 3 papillary carcinomas. Within the follow-up time (median: 24 months) no tumor recurrence or major complication was detected. No significant change in serum creatinine level was noted. The cancer-specific survival rate was 100% (15 of 15), and 1-, 2-, and 3-year overall survival rates were 100%, 93.3%, and 93.3%, respectively.
Percutaneous MWA is an effective and safe treatment option for stage T1a RCCs in solitary kidney patients; it can achieve high complete ablation rate in selected lesions of appropriate size and location.
回顾性评估经皮微波消融（MWA）治疗孤立肾 T1a 期肾细胞癌（RCC）的早期临床结果。
2016 年 10 月至 2020 年 7 月，15 例孤立肾 T1aN0M0 期经活检证实的 RCC 患者接受 CT 引导下经皮微波消融术。患者在 MWA 前、MWA 后 1 天和最近一次随访时进行增强 CT 或磁共振成像检查，此后每 6 个月随访一次。收集每位患者 MWA 前、MWA 后 1 天和最近一次记录的血清肌酐水平。评估技术疗效、局部复发、生存率和并发症。
16 个肿瘤（100%）均达到完全消融，包括 13 个透明细胞癌和 3 个乳头状癌。在随访时间（中位数：24 个月）内，未发现肿瘤复发或重大并发症。血清肌酐水平无明显变化。癌症特异性生存率为 100%（15/15），1、2、3 年总生存率分别为 100%、93.3%和 93.3%。
经皮 MWA 是治疗孤立肾 T1a 期 RCC 的有效且安全的选择；对于适当大小和位置的选定病变，可实现高完全消融率。
